8,949 results match your criteria: "Lymph Node Dissection Pelvic"
Surg Oncol
December 2024
Department of Urology, School of Medicine, Ankara University, Ankara, Turkey. Electronic address:
Background: Multiparametric magnetic resonance imaging (mpMRI) is used as a current marker in preoperative staging and surgical decision-making, but current evidence on predicting post-surgical oncological outcomes based on preoperative mpMRI findings is limited. In this study We aimed to develop a risk classification based on mpMRI and mpMRI-derived biopsy findings to predict early biochemical recurrence (BCR) after radical prostatectomy.
Methods: Between January 2017 and January 2023, the data of 289 patients who underwent mpMRI, transrectal ultrasound-guided cognitive and fusion targeted biopsies, and subsequent radical prostatectomy (RP) with or without pelvic lymph node dissection in a single center were retrospectively re-evaluated.
J Urol
September 2024
Department of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Ann Surg Oncol
December 2024
Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Womens Health (Lond)
September 2024
Department of Surgical Oncology, Salah Azaiez Institute, Faculty of Medicine of Tunis, University of Tunis El Manar, Tunisia.
BMC Gastroenterol
September 2024
Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465, Kaji-Cho, Kamigyo-Ku, Kyoto, 602-8566, Japan.
Background: Postoperative neurogenic bladder (PONB) frequently occurs as a complication after rectal cancer surgery. This study aimed to analyze risk factors for developing PONB after rectal cancer surgery, particularly the association between pelvic anatomy and visceral fat mass.
Methods: We included 138 patients who underwent rectal resection for lower rectal cancer in our department between 2017 and 2021.
Int J Gynecol Cancer
November 2024
Koç University School of Medicine, Istanbul, Turkey.
Introduction: Assessment of retroperitoneal nodes is an important part of the surgical staging of gynecologic cancers. Although pelvic and paraaortic lymphadenectomy have been widely described by different authors, there is little consensus on the description of the different surgical steps for each procedure. An Intergroup Committee on Onco-Gyn Minimally Invasive Surgery has been established with members of the European Society for Gynecological Endoscopy (ESGE), European Society of Gynaecological Oncology (ESGO) and the Society of European Robotic Gynaecological Surgery (SERGS).
View Article and Find Full Text PDFPLoS One
September 2024
Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.
Background And Objective: Although radical cystectomy (RC) with pelvic lymph node dissection (PLND) is the standard treatment of muscle invasive bladder cancer, it may cause lymphatic leakage. Recent studies describe lymphatic embolization (LE) as an option to manage post-operative lymphatic leakage. Hence, this study evaluated the outcome of LE in patients receiving RC and analyzed factors associated with outcomes.
View Article and Find Full Text PDFInt J Gynecol Cancer
September 2024
Department of Obstetrics and Gynecology, University of Insubria Faculty of Medicine and Surgery, Varese, Italy.
J Robot Surg
September 2024
Department of Urology, Affiliated Hospital of North Sichuan Medical College, No. 1 Mao Yuan South Road, Shunqing, Nanchong, 637000, Sichuan, People's Republic of China.
Because of the increasing popularity of Hugo RAS as a surgical platform, a comparison examination of intraoperative and oncological outcomes across DaVinci and Hugo RAS robotic surgery platforms is urgently needed. We carried out a comprehensive review and meta-analysis of the literature of current research, comprehensively searching PubMed, Cochrane and Embase for eligible studies comparing the results between the DaVinci and Hugo RAS. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria were followed in the conduct of this study, with language restricted to English and a final search date of June 2024.
View Article and Find Full Text PDFCureus
August 2024
First Propaedeutic Department of Surgery, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, GRC.
Lateral lymph node dissection and its inclusion in the treatment of rectal cancer is a controversial issue, with great differences, especially between Eastern and Western countries. Studies try to highlight the superiority of resection of these lymph nodes compared to simple mesorectal resection in terms of local recurrence of the disease, the overall survival of patients, and additional postoperative complications. In this study, the modern literature was reviewed, with the ultimate goal of clarifying the exact importance of lateral lymph node dissection, in terms of oncological outcome in patients with cancer of the middle and lower rectum, by studying the involvement of this lymph node dispersion in terms of local recurrence and overall survival of patients with rectal cancer.
View Article and Find Full Text PDFFront Oncol
September 2024
Department of Gynecology, The Affiliated Hospital of Qingdao University, Qingdao, China.
The manifestation of a giant ovarian yolk sac tumor during late pregnancy is relatively rare. A yolk sac tumor is a highly malignant germ cell tumor that originates from primitive germ cells. It is characterized by yolk sac differentiation .
View Article and Find Full Text PDFInt J Colorectal Dis
September 2024
Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.
Purpose: The population in Western countries differs significantly from that in Eastern countries, and the prevalence of lateral pelvic lymph node (LPLN) involvement in Western populations remains largely unknown due to the limited application of LPLN dissection (LPLND). This discrepancy is primarily attributed to the higher body mass index commonly observed in Western populations, which increases the risk of intraoperative complications. Consequently, the aim of this study is to describe a specific Western clinico-radiological selection tool for LPLND, namely, the lateral pelvic lymph node positivity (LPLNP) score.
View Article and Find Full Text PDFWorld J Clin Cases
September 2024
Division of Urology, Department of Surgery, Tungs' Taichung MetroHarbor Hospital, Taichung 435403, Taiwan.
Background: Adenocarcinoma is the most common subtype of prostate cancer. Prostatic urothelial carcinoma (UC) typically originates from the prostatic urethra. The concurrent occurrence of adenocarcinoma and UC of the prostate gland is uncommon.
View Article and Find Full Text PDFTransl Androl Urol
August 2024
Department of Urology, George Washington University School of Medicine, Washington, DC, USA.
Transl Androl Urol
August 2024
Department of Urologic Oncology Surgery, Miami Cancer Institute, Miami, Florida, USA.
Background: Neoadjuvant chemotherapy with radical cystectomy (RC) is the preferred first-line treatment for localized muscle-invasive bladder cancer (MIBC). Due to the concern about morbidity associated with RC, the elderly population considers bladder preservation alternatives. Guidelines suggest partial cystectomy (PC) can be considered a viable option in carefully selected individuals.
View Article and Find Full Text PDFUrol Oncol
January 2025
Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY.
Background And Objective: Neoadjuvant therapy followed by radical cystectomy with lymphadenectomy remains the gold standard of treatment in patients with muscle-invasive bladder cancer. Pathologically positive lymph node (pN+) disease is known to convey a poor prognosis. Tumor-informed circulating tumor DNA (ctDNA) has emerged as a possible novel prognostic biomarker in the field.
View Article and Find Full Text PDFJ Clin Med
August 2024
University Center of Excellence in Urology, Department of Minimally Invasive and Robotic Urology, Wroclaw Medical University, 50-556 Wroclaw, Poland.
Cancers (Basel)
August 2024
Gynaecological Cancer Research Group, School of Women' and Children's Health, Faculty of Medicine & Health, University of New South Wales, Sydney 2052, Australia.
Vulvar cancer is a rare disease, and cure rates were low until the mid-20th century. The introduction of an en bloc radical vulvectomy and bilateral groin and pelvic lymph node dissection saw them rise from 15-20% to 60-70%. However, this very radical surgery was associated with high physical and psychological morbidity.
View Article and Find Full Text PDFEur J Cancer
November 2024
Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital (Central and Eastern European Gynecologic Oncology Group, CEEGOG), Prague, Czech Republic.
Aim: The aim of this study was to assess whether the use of sentinel lymph node (SLN) in addition to lymphadenectomy was associated with survival benefit in patients with early-stage cervical cancer.
Methods: International, multicenter, retrospective study.
Inclusion Criteria: cervical cancer treated between 01/2007 and 12/2016 by surgery only; squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, FIGO 2009 stage IB1-IIA2, negative surgical margins, and laparotomy approach.
Taiwan J Obstet Gynecol
September 2024
Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan; Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; Female Cancer Foundation, Taipei, Taiwan; Department of Medical Research, China Medical University Hospital, Taichung, Taiwan. Electronic address:
The current review described a 55-year woman using 28 months to finish her surgery-based radiation-free multimodality treatment journey to fight International Federation of Gynaecology & Obstetrics (FIGO) 2018 clinical stage IIA2 (cT2aN0M0) squamous cell carcinoma (SCC) of the cervix. She received six cycles of perioperative adjuvant therapy, including three cycles of neoadjuvant therapy (NAT) and three cycles of postoperative adjuvant therapy by using combination of dose-dense chemotherapy (CT, weekly paclitaxel 80 mg/m+triweekly cisplatin 40 mg/m), immunotherapy (IO, triweekly pembrolizumab 200 mg) and half-dose anti-angiogenic agent (triweekly bevacizumab 7.5 mg/kg) plus interval radical surgery (radical hysterectomy + bilateral salpingo-oophorectomy + bilateral pelvic lymph node dissection + para-aortic lymph node sampling) and following maintenance therapy with monthly 22 cycles of half-dose of IO (pembrolizumab 100 mg) and concomitant 4 cycles of single-agent CT (paclitaxel 175 mg/m) and 18 cycles of half-dose anti-angiogenic agent (bevacizumab 7.
View Article and Find Full Text PDFClin Genitourin Cancer
December 2024
Department of Urology, University of California San Diego School of Medicine, La Jolla, CA. Electronic address:
Objective: To evaluate the role of pelvic lymph node dissection (PLND) in patients diagnosed with high-risk nonmuscle-invasive bladder cancer (NMIBC) undergoing radical cystectomy (RC) using a national cohort of NMIBC patients.
Methods: A cohort of patients diagnosed with NMIBC cancer with urothelial carcinoma from the National Cancer Database (NCDB) between 2004 and 2019 was utilized. The cohort consists of patients who have not received BCG and underwent upfront radical cystectomy or pelvic exenteration.
Eur J Surg Oncol
November 2024
School of Medicine, Nankai University, Tianjin, 300071, China; Tianjin Central Hospital of Obstetrics and Gynecology, Tianjin, China. Electronic address:
Objective: The survival outcomes of Stage IIIC1 in FIGO 2018 showed significant heterogeneity and it seems unreasonable to administer a uniform treatment regimen for Stage IIIC1 patients. This study aimed to assess the survival outcomes among patients with locally advanced cervical cancer based on various lymph node statuses, T-stage classifications, and treatment modalities.
Methods: This is a population-based cohort study utilizing the Surveillance, Epidemiology, and End Results Program from 2004 to 2018.
Gynecol Oncol Rep
October 2024
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of California, Irvine Medical Center, Orange, CA, USA.
Introduction: Pembrolizumab is an immunotherapy approved for use in patients with a combined positive score (CPS) greater than one with recurrent cervical cancer. In clinical practice, the CPS score is not typically analyzed in both primary and metastatic specimens.
Case Descriptions: Case 1A 42-year-old woman with history of an abnormal pap smears who presented with a large pelvic mass with initial biopsy of cervix demonstrating squamous cell carcinoma with negative PDL1 expression and a CPS score of 0.
Int J Gynecol Cancer
December 2024
Gynecology and Obstetrics 1, Department of Surgical Sciences, S. Anna Hospital, City of Health and Science, University of Turin, Turin, Italy.
Objective: Missing occult para-aortic lymph node metastasis is one of the primary concerns of sentinel lymph node biopsy in endometrial cancer. Our study aimed to evaluate the relationship between intrauterine cancer site and isolated para-aortic lymph node metastasis to tailor treatment and reduce the false negative rate of the sentinel lymph node procedure.
Methods: A retrospective, multicenter, case control study was performed in four international centers.
Eur J Nucl Med Mol Imaging
October 2024
Department of Urology, University Hospitals Leuven, Leuven, Belgium.